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Since its development in 2002, transcatheter aortic valve implantation (TAVI) has rapidly evolved and is currently used worldwide to treat patients with severe aortic valve stenosis who have a high surgical risk or a contraindication to open surgery.
1,2 The transfemoral delivery route is the most commonly used approach and transaxillary or subclavian strategies represent alternative options in case of anatomical difficulties. 3 Several studies including retrospective case series or randomized trials have addressed the safety of the procedure and its long-term impact on patient outcome and have identified vascular complications as one of the main adverse effects. [4] [5] [6] [7] [8] [9] However, discrepancies regarding the incidence of vascular complications have been reported and may, at least partly, be explained by heterogenic definitions of these complications. 8, 10 In 2011, the publication of the Valve Academic Research Consortium (VARC) classification improved the standardization to assess vascular complications during TAVI. 11, 12 This classification has been revised in 2012 and provides definitions of major and minor vascular access site and access-related complications 13 (Tables 1 and 2) . Since its creation, this classification has been widely used to assess vascular complications during TAVI and has improved consistency and uniformity between studies. 8 While the classification has provided big advances to assess vascular complications during TAVI, several issues should be taken into consideration to evaluate percutaneous access-related injuries and their management.
First, patients with severe aortic stenosis eligible to TAVI often have associated comorbidities including cardiovascular risk factors, and the prevalence of peripheral artery disease in patients with TAVI is estimated to be 20% to 30%.
14 Hence, investigators should be aware that some patients may have preexisting peripheral arterial lesions, which should be taken into consideration separately to clearly distinguish them from vascular lesions induced by the percutaneous approach. In that context, preoperative imaging including computed tomography scan or angiography should be carefully analyzed in order to distinguish preexisting lesions such as dissection or stenosis from access-related de novo lesions.
Second, vascular outcomes that occur peroperatively should be clearly distinguished from postoperative complications. Indeed, the early identification of perioperative lesions and their endovascular management could prevent and reduce postoperative complications rate. 15 The absence of a clear distinction between perioperative events and postoperative vascular complications could lead to a discrepancy between clinical studies, and systematic completion angiography should help identifying peroperative events. At the end, a 3-type arterial lesion categorization is suggested to distinguish (1) preexisting arterial lesions requiring endovascular management for access, (2) identified periprocedural events leading to immediate endovascular treatment, (3) postoperative complication identified postoperatively. In addition, considering TAVI as an endovascular procedure, open surgery for treating a peroperative lesion should also be considered as a complication. Another concern is the precise definition of vascular lesions including stenosis, perforation, rupture, and hematoma. The degree and the location of stenosis should be clearly defined by the investigators. Besides, the distinction between perforation and rupture can be difficult to distinguish in practice. Criteria used to define hematomas should also be clearly stated by investigators as it may impact on results. In addition, for some patients, investigators can encounter difficulty to determine whether the vascular complication is directly linked to the access site management. As an example, the severity of bleeding represents one of the criteria used to distinguish minor and major complications (Table 1 and 2), but given the impact of anticoagulant treatment used during TAVI, it can be difficult to determine whether bleeding is directly caused by a vascular complication rather than the systemic treatment. Moreover, indication of blood transfusion related to peroperative blood loss is also linked to the preoperative condition of the patient. Finally, the localization of vascular lesions and their perioperative management is rarely reported in clinical studies, despite the potential impact of these 2 factors on postoperative outcome. 15 Although VARC-2 classification has offered the opportunity to better standardize the assessment of vascular complications related to TAVI, recent publications suggest that complementary criteria should be added to specifically assess access-site and access-related injury. Sedaghat et al proposed a classification of 4 types of access-related injury based on angiography and their results suggest that such an approach may be a useful tool. 16 Percutaneous approaches are commonly used for other vascular diseases including endovascular aortic aneurysm repair (EVAR), and specific classifications have been developed to evaluate vascular complications related to the device. 17 Similarly, adjunctive procedures required to efficiently manage EVAR have been precisely defined and classified into preoperative, planned or unplanned intraoperative, and postoperative maneuvers. 17 Several points used in such classifications may be useful to complement criteria currently used to evaluate vascular access-related injury during TAVI.
Additional definitions and scoring of vascular lesions associated with their identification by a systematic perioperative angiographic analysis and description of adjunctive procedures may improve the assessment of access-site related injury in the context of TAVI. This field is in constant evolution and we truly believe that new approaches are to be expected within the next few years. Failure of a closure device to achieve haemostasis at the arteriotomy site leading to alternative treatment (other than manual compression or adjunctive endovascular ballooning)
